United States News All stories

MediciNova (NASDAQ:MNOV) reported topline results from a Phase 2 placebo-controlled trial evaluating MN-001, also known as tipelukast, in patients with type 2 diabetes, fatty liver disease, and elevated triglycerides.

Gray Media (NYSE:GTN) raised its third-quarter 2026 political advertising revenue guidance to $188 million–$195 million, compared with its previous forecast of $165 million–$185 million.

Zymeworks (NASDAQ:ZYME) completed its acquisition of Theravance Biopharma for $17 per share, adding rights to YUPELRI profit sharing and international royalties.

Hudbay Minerals (NYSE:HBM) extended the reserve mine life of its Snow Lake operations in Manitoba to 2043 under an updated plan that increases projected gold production.

IDEAYA Biosciences (NASDAQ:IDYA) promoted Dr. Michael White from chief scientific officer to president of research and development, effective September 28, 2026.

U.S.-listed gold miners fell in premarket trading as spot gold prices declined 3.2% to $4,149.89 per ounce, reaching their lowest level since August 5.

NVIDIA (NASDAQ:NVDA) introduced its Open Agent Safety Platform, an open-source framework designed to provide controls for AI agents through runtime monitoring and policy enforcement tools.

Amprius Technologies (NYSE:AMPX) received a grant of up to $75 million from the U.S. Department of War to retrofit an existing domestic production line for high-energy-density batteries used in unmanned aerial systems.

Brent crude oil prices rose 2.49% on Monday after U.S. President Donald Trump rejected a peace proposal from Iran aimed at resolving their conflict and reopening the Strait of Hormuz.

Webuy Global (NASDAQ:WBUY) reported first-half 2026 revenue from continuing operations of US$14.31 million following its exit from the Singapore grocery business.

NIO (NYSE:NIO) signed definitive agreements with subsidiaries of Geely Holding Group covering investments and asset transactions involving NIO Power’s battery swapping and charging businesses.

HUTCHMED (NASDAQ:HCM) initiated a global Phase Ia clinical trial of HMPL-A830 in patients with advanced solid tumors, with the first patient receiving a dose in China on September 24, 2026.

QIAGEN (NYSE:QGEN) received U.S. Food and Drug Administration clearance for its QIAstat-Dx BCID GN Plus AMR Panel, expanding access to its bloodstream infection testing portfolio for U.S. laboratories.

Burford Capital (NYSE:BUR) said it has a financial entitlement in the Taction Technology v. Apple patent case, where a jury awarded the plaintiff $5.7 billion after the market closed on September 25, 2026.

Tandem Diabetes Care (NASDAQ:TNDM) announced that Tandem Mobi, its automated insulin delivery system, is now available in 12 countries outside the United States, with the company accepting orders and shipping to eligible customers.

Planet Labs PBC (NYSE:PL) announced that Pelican-12, an updated second-generation high-resolution Pelican satellite, arrived at Cape Canaveral Space Force Station ahead of its planned launch aboard SpaceX’s Bandwagon-5 rideshare mission.

Astrotech (NASDAQ:ASTC) reported fiscal 2026 revenue of $913,000 for the year ended June 30, 2026, as the company continued commercial deployment of its analytical technology platforms.

Nektar Therapeutics (NASDAQ:NKTR) received a jury verdict awarding the company $90 million in damages after a court found Eli Lilly (NYSE:LLY) breached the implied covenant of good faith and fair dealing related to a prior rezpegaldesleukin license agreement.

Firefly Neuroscience (NASDAQ:AIFF) and NeuroSigma announced a partnership to introduce NeuroSigma’s Monarch eTNS System to clinicians using Firefly’s Evoke brain-function assessment platform.

XCF Global (NASDAQ:SAFX) reported more than $10 million in August revenue from renewable diesel shipped from its Reno facility after the site restarted operations in July 2026.

Johnson & Johnson (NYSE:JNJ) reported that TREMFYA met its primary and major secondary endpoints in the Phase 4 STAR study evaluating adults with active psoriatic arthritis and MRI-confirmed axial inflammation.

Legend Biotech (NASDAQ:LEGN) reported five-year results from the Phase 2 CARTITUDE-2 Cohort A study showing that 10 of 20 patients treated with a single CARVYKTI infusion remained alive and progression-free without further anti-myeloma treatment.

Ocugen (NASDAQ:OCGN) announced that OCU400 received provisional approval and priority designation in The Bahamas for the treatment of retinitis pigmentosa, an inherited eye disorder.

C4 Therapeutics (NASDAQ:CCCC) presented new biomarker data from two Phase 1 multiple myeloma combination trials evaluating cemsidomide, including studies with dexamethasone and elranatamab.